Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €12.39 EUR
Change Today +0.06 / 0.49%
Volume 2.5K
CEREN On Other Exchanges
EN Paris
As of 11:35 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

cerenis therapeutics holding (CEREN) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/1/15 - €14.44
52 Week Low
04/14/15 - €10.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cerenis therapeutics holding (CEREN) Related Businessweek News

No Related Businessweek News Found

cerenis therapeutics holding (CEREN) Details

Cerenis Therapeutics Holding SA, a biopharmaceutical company, discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases comprising non-alcoholic steatohepatitis. It is developing HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients; and HDL elevators for patients with low HDL. The company develops CER-001, an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and phospholipids, which is in phase II clinical trials designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL. Cerenis Therapeutics Holding SA was founded in 2005 and is based in Labege, France.

9 Employees
Last Reported Date: 03/4/15
Founded in 2005

cerenis therapeutics holding (CEREN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cerenis therapeutics holding (CEREN) Key Developments

Cerenis Therapeutics Holding SA Reports Earnings Results for the First Six Months Ended June 30, 2015

Cerenis Therapeutics Holding SA reported earnings results for the first six months ended June 30, 2015. For the period, the company reported operating loss of €6,303,000 against €3,205,000 a year ago. Net loss was €7,062,000 against €3,619,000 a year ago.

Cerenis Therapeutics Announces the Results of the LOCATION Study

Cerenis Therapeutics announced the results of the LOCATION clinical study, which evaluated the selectivity of CER-001, an HDL mimetic made of recombinant human apolipoprotein A-I (apoA-I) and phospholipids, for carotid plaques in patients with advanced atherosclerotic disease. The LOCATION study provides the first evidence of CER-001 selective targeting of atherosclerotic plaques in patients, and of the role of plaque permeability in plaque penetration by an HDL mimetic. The study evaluated 8 patients with >50% atherosclerotic stenosis of the carotid artery who received an infusion of CER-001 (3 mg/kg body weight) labeled with Zirconium-89, a tracer suited for PET/CT imaging, to determine the extent to which CER-001 targets and penetrates atherosclerotic plaques and the effect on cholesterol efflux, a marker which is inversely related to the incidence of adverse cardiovascular events. CER-001 penetrates atherosclerotic plaques: Using serial PET/CT imaging, the investigators were able to show that plaque uptake of CER-001 increased significantly 24 hours after infusion (14%), and remained increased up to 48 hours (12%). This is the first demonstration of plaque penetration by CER-001 in patients with atherosclerotic disease. CER-001 preferentially targets atherosclerotic plaques: By looking at specific segments of the carotid arteries with and without atherosclerotic plaques, the investigators were able to show that the uptake of CER-001 was higher in segments with plaques than in non-plaque segments demonstrating that infused CER-001 preferentially enters atherosclerotic plaques in patients. Using an imaging technique that allows the evaluation of the permeability of atherosclerotic plaques, they were also able to show that the extent to which CER-001 enters the plaque is determined by the plaque’s permeability. This observation supports the concept and may be particularly relevant for the selection of patients most likely to benefit from apoA-I-containing HDL-mimetic therapy based on plaque permeability. CER-001 increases cholesterol efflux capacity: In addition, by collecting serial blood samples, the investigators showed that one hour after CER-001 infusion plasma-mediated cholesterol efflux increased by 13.8% and mean plasma apoA-I levels increased by 9.9 mg/dL. Both apoA-I levels and cholesterol efflux capacity returned to baseline values after 24 hours. The results of the LOCATION study are consistent with the findings of the CER-001 clinical program to date, which have shown that CER-001 effectively mobilises cholesterol and regress atherosclerosis. The findings validate plaques targeting with CER-001 at the dose being investigated in the planned CARAT study (NCT02484378), a double-blind, placebo-controlled, phase II study assessing the effect of CER-001 on atherosclerosis regression in patients with acute coronary syndrome.

Cerenis Therapeutics Holding SA to Report Q2, 2015 Sales/Trading Statement Results on Jul 28, 2015

Cerenis Therapeutics Holding SA announced that they will report Q2, 2015 sales/trading statement results on Jul 28, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEREN:FP €12.39 EUR +0.06

CEREN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CEREN.
View Industry Companies

Industry Analysis


Industry Average

Valuation CEREN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERENIS THERAPEUTICS HOLDING, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at